Journal article · 2023 · Open access
The Antioxidant TEMPOL Protects Human Hematopoietic Stem Cells From Culture-Mediated Loss of Functions
Stem Cells Translational Medicine, 12(10), 676–688 · Published 24 August 2023 · DOI 10.1093/stcltm/szad049
In brief
“The Antioxidant TEMPOL Protects Human Hematopoietic Stem Cells From Culture-Mediated Loss of Functions” is a 2023 journal article by Elia Henry and 10 co-authors, published in Stem Cells Translational Medicine. OpenAlex counts 9 citations as of 18 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at Stem Cells Translational Medicine.
- Citations
- 9
- Most cited in
- 2024 (6)
- Field-weighted impact
- 1.50
- References
- 71
- Authors
- 11
Abstract
In a steady state, hematopoietic stem cells (HSC) exhibit very low levels of reactive oxygen species (ROS). Upon stress, HSC get activated and enter into proliferation and differentiation process to ensure blood cell regeneration. Once activated, their levels of ROS increase, as messengers to mediate their proliferation and differentiation programs. However, at the end of the stress episode, ROS levels need to return to normal to avoid HSC exhaustion. It was shown that antioxidants can prevent loss of HSC self-renewal potential in several contexts such as aging or after exposure to low doses of irradiation suggesting that antioxidants can be used to maintain HSC functional properties upon culture-induced stress. Indeed, in humans, HSC are increasingly used for cell and gene therapy approaches, requiring them to be cultured for several days. As expected, we show that a short culture period leads to drastic defects in HSC functional properties. Moreover, a switch of HSC transcriptional program from stemness to differentiation was evidenced in cultured HSC. Interestingly, cultured-HSC treated with 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl (4-hydroxy-TEMPO or Tempol) exhibited a higher clonogenic potential in secondary colony forming unit cell (CFU-C) assay and higher reconstitution potential in xenograft model, compared to untreated cultured-HSC. By transcriptomic analyses combined with serial CFU-C assays, we show that Tempol, which mimics superoxide dismutase, protects HSC from culture-induced stress partly through VEGFα signaling. Thus, we demonstrate that adding Tempol leads to the protection of HSC functional properties during ex vivo culture.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Henry, E., Picou, F., Barroca, V., Déchamps, N., Sobrino, S., Six, E. M., Chenevier‐Gobeaux, C., Auberger, P., Hérault, O., Pflumio, F., & Arcangeli, M.-L. (2023). The Antioxidant TEMPOL Protects Human Hematopoietic Stem Cells From Culture-Mediated Loss of Functions. Stem Cells Translational Medicine, 12(10), 676–688. https://doi.org/10.1093/stcltm/szad049
MLA 9
Henry, Elia, et al. “The Antioxidant TEMPOL Protects Human Hematopoietic Stem Cells From Culture-Mediated Loss of Functions.” Stem Cells Translational Medicine, vol. 12, no. 10, 2023, pp. 676–688. https://doi.org/10.1093/stcltm/szad049.
Chicago
Henry, Elia, Frédéric Picou, Vilma Barroca, Nathalie Déchamps, Steicy Sobrino, Emmanuelle M. Six, Camille Chenevier‐Gobeaux, et al. 2023. “The Antioxidant TEMPOL Protects Human Hematopoietic Stem Cells From Culture-Mediated Loss of Functions.” Stem Cells Translational Medicine 12 (10): 676–688. https://doi.org/10.1093/stcltm/szad049.
Harvard
Henry, E. et al. (2023) ‘The Antioxidant TEMPOL Protects Human Hematopoietic Stem Cells From Culture-Mediated Loss of Functions’, Stem Cells Translational Medicine, 12(10), pp. 676–688. doi:10.1093/stcltm/szad049.
IEEE
E. Henry et al., “The Antioxidant TEMPOL Protects Human Hematopoietic Stem Cells From Culture-Mediated Loss of Functions,” Stem Cells Translational Medicine, vol. 12, no. 10, pp. 676–688, 2023, doi: 10.1093/stcltm/szad049.
BibTeX
@article{henry2023antioxidant,
title = {{The Antioxidant TEMPOL Protects Human Hematopoietic Stem Cells From Culture-Mediated Loss of Functions}},
author = {Henry, Elia and Picou, Frédéric and Barroca, Vilma and Déchamps, Nathalie and Sobrino, Steicy and Six, Emmanuelle M. and Chenevier‐Gobeaux, Camille and Auberger, Patrick and Hérault, Olivier and Pflumio, Françoise and Arcangeli, Marie-Laure},
journal = {Stem Cells Translational Medicine},
year = {2023},
volume = {12},
number = {10},
pages = {676--688},
doi = {10.1093/stcltm/szad049},
url = {https://doi.org/10.1093/stcltm/szad049}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2024 | 6 | |
| 2025 | 1 | |
| 2026 | 2 |
Its field-weighted citation impact is 1.50: it has been cited 1.50 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- hematopoietic stem cells
- tempol
- antioxidants
- reactive oxygen species
- stem cell self-renewal
- clonogenicity
- superoxide dismutase mimicry
- stemness
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Henry, E., Picou, F., Barroca, V., Déchamps, N., Sobrino, S., Six, E. M., Chenevier‐Gobeaux, C., Auberger, P., Hérault, O., Pflumio, F., & Arcangeli, M.-L. (2023). The Antioxidant TEMPOL Protects Human Hematopoietic Stem Cells From Culture-Mediated Loss of Functions. Stem Cells Translational Medicine, 12(10), 676–688. https://doi.org/10.1093/stcltm/szad049
How many times has this paper been cited?
9 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Stem Cells Translational Medicine: sign in and open the PDF from this page.
Who wrote this paper?
Elia Henry, Frédéric Picou, Vilma Barroca, Nathalie Déchamps, Steicy Sobrino, Emmanuelle M. Six, Camille Chenevier‐Gobeaux, Patrick Auberger, Olivier Hérault, Françoise Pflumio, Marie-Laure Arcangeli.
What is the DOI of this paper?
10.1093/stcltm/szad049, permanently at https://doi.org/10.1093/stcltm/szad049. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.